middle.news
Invex Adds Multiple Sclerosis Trial With A$10 Million Funding Plan
12:06pm on Friday 30th of October, 2026 AEDT
•
Biotechnology
Read Story
Invex Adds Multiple Sclerosis Trial With A$10 Million Funding Plan
12:06pm on Friday 30th of October, 2026 AEDT
Key Points
Proposed Rekover acquisition funded entirely with shares and performance rights
A$10 million placement priced at A$0.08 per share
REVIVE Phase 2a study targets multiple sclerosis-related chronic optic neuropathy
September-quarter operating cash outflow of A$425,000
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Invex Therapeutics (ASX:IXC)
OPEN ARTICLE